PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Caroverine→

Caroverine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
23465-76-1
Molecular formula
C22H27N3O2
Molecular weight
365.5 g/mol
Drug class
Smooth-muscle spasmolyticcalcium-channel and phosphodiesterase inhibitor properties
Mechanism of action
Relaxes smooth muscle through calcium-channel blocking and phosphodiesterase-inhibitory effects. Proposed additional effects on glutamatergic signalling have been described, but the clinical mechanism is not fully established.
Indications / reported uses
  • Used in some countries for symptomatic relief of visceral smooth-muscle spasm and selected otological or vestibular complaints; indications and evidence vary by jurisdiction and product

Sources: NLM MeSH — Caroverine · PubMed — Caroverine pharmacology and clinical use · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Caroverine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Caroverine Permitted Daily Exposure (PDE) report (the Caroverine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Caroverine Occupational Exposure Limit (OEL) report (the Caroverine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.